Method of preparing transplant tissue to reduce immunogenicity upon implantation

• US 5,613,982 A
• Filed: 06/05/1995
• Issued: 03/25/1997
• Est. Priority Date: 03/14/1994
• Status: Expired due to Term

• Current Assignee: Cryolife Incorporated
• Original Assignee: Cryolife Incorporated
• Inventors: Goldstein, Steven
• Primary Examiner(s): Prebilic, Paul B.
• Application Number:
  US08/463,455
• Time in Patent Office: 659 Days
• Field of Search: 623/11, 623/66, 128/898, 435/240.241, 435/240.243, 8/94.11, 8/94.18
• US Class Current: 424/423
• CPC Class Codes: A61L 2430/40 Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3625 Vascular tissue, e.g. heart valves
• CPC Class Codes: A61L 27/3683 subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: A61L 27/38 containing added animal cells organs or tissue containing native cells A61L27/36
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/3895 using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
• CPC Class Codes: A61L 27/507 for artificial blood vessels apparatus for applying cells on a blood vessel prosthesis A61F2/062
• CPC Class Codes: Y10S 623/92 Method or apparatus for preparing or treating prosthetic
• CPC Class Codes: Y10S 623/921 Blood vessel

Abstract

This disclosure includes a method for generating a functional hybrid bioprosthesis. Tissue formed naturally of interstitial collagens is treated to kill native cells and remove potentially immunologically active soluble molecules. Then it may be treated sequentially with extracellular matrix adhesion factor such as fibronectin, extracellular matrix glycosaminoglycan such as heparin, and growth factor appropriate to the cell type required to function within the matrix, and incubating the transplant tissue matrix with cells that are either allogeneic or autologous for the recipient thereby imparting to the matrix the characteristics of the cell type and tissue selected. Tissues with a variety of functional bioactivities can thus be formed in vitro prior to graft transplantation or implantation which will exhibit reduced or no stimulation of an immunological response in the recipient.

Claims

1. An in vitro process for generating implants or grafts of collagenous, connective, or vascular tissue which are xenogeneic to a human recipient comprising decellularizing a natural tissue to produce a tissue matrix, the tissue matrix is next washed to remove cellular antigens, or extracellular antigens, or both, followed by treatment of the tissue matrix with adhesion factors comprised of fibronectin and heparin effective to promote attachment thereto of fibroblast cells immunologically acceptable to the implant or graft recipient, next the tissue matrix is treated with adhesion factor and is repopulated by incubating the matrix in the presence of the fibroblast cells and fibroblast growth factor until such cellular repopulation provides a vitalized tissue histologically similar to the corresponding natural tissue, and wherein the implant tissue generated is mechanically, biochemically and immunologically suitable for implantation.

2. The process of claim 1 wherein the fibronectin comprises human plasma fibronectin or human tissue fibronectin.

3. The process of claim 2 wherein the natural tissue is collagenous tissue.

4. The process of claim 2 wherein the natural tissue is connective tissue.

5. The process of claim 3 wherein the fibroblast cells are cultured human fibroblast cells.

6. The process of claim 5 wherein the natural tissue is heart valve tissue, and wherein the repopulation cells are human fibroblast cells.

7. The process of claim 1 further comprising the step of cryopreserving the tissue matrix at a stage prior to the cellular repopulation step.

8. The process of claim 4 wherein the natural tissue is decellularized by treatments including treatment with nucleases so as to limit generation of new immunological sites.

9. The process of claim 1 wherein the heparin adheres fibronectin to portions of the tissue matrix, and wherein the fibroblast-growth factor is basic human recombinant fibroblast growth factor.

10. The process of claim 9 wherein the natural tissue is aortic or pulmonary heart valve tissue.

11. The process of claim 1 wherein the fibroblast cells are autogenous cells.

12. The process of claim 1 wherein the fibroblast cells are allogenous cells.

13. The process of claim 1 wherein the fibroblast cells are derived from stable cell lines.

14. The process of claim 1 wherein the fibroblast cells are modified genetically by techniques of stable transfection with exogenous genetic material.

15. The process of claim 1 wherein the fibroblast cells are of human origin and are modified to be substantially non-immunogenic upon implantation.

16. The process of claim 1 wherein the fibroblast cells are of human origin and are modified to express specific proteins.

17. The process of claim 1 wherein the tissue is of porcine or bovine origin, the adhesion matrix factor comprises purified fibronectin and heparin, and wherein the repopulating cells are human fibroblast cells in the presence of effective amounts of basic or acid fibroblast growth factor and the implant tissue produced is a xenogeneic implant substantially free of adverse immunological response upon implantation into a human.

18. The process of claim 1 wherein the decellularization step comprises treating the tissues with a low ionic strength solution and nucleases.

19. The process of claim 18 wherein the low ionic strength solution of nucleases includes at least one member selected from the group consisting of RNAase A, DNAase I, EcoR I and Hind III.

20. The process of claim 1 wherein the natural tissue is collagenous tissue;

the tissue is decellularized by treatment with a low ionic strength solution and DNAase I and RNAase A, effective to eliminate native cells and provide a tissue matrix of limited immunogenicity; and

the tissue matrix is treated with an amount of a buffered solution containing fibronectin and heparin sulfate effective to provide sites associated with the tissue matrix which facilitate fibroblast cell attachment thereto; and

wherein the tissue matrix is repopulated by incubating it together with fibroblast cells of human origin in the presence of an amount of fibroblast growth factor, effective to facilitate cell growth and repopulate the tissue matrix with fibroblast cells.